Sort
16,300 grants matching “fatty liver disease”
Functional consequences of plasmalogens - Membrane curvature and lipid miscibility
$2,500Alison Leonard · University Of Delaware · F32 · FY2021 · GM
Lifecourse dietary exposures and offspring hepatic fat in early childhood: a nutrigenic approach
$2,500Catherine Cioffi Cohen · University Of Colorado Denver · F32 · FY2023 · DK
Characterizing the Impact of Gestational Diabetes on Immunity and Group B Streptococcal Virulence in the Maternal Reproductive Tract
$2,500Vicki Mercado · Baylor College Of Medicine · F31 · FY2022 · AI
NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS
$2,489Kenneth Cusi · University Of Texas Hlth Science Center · M01 · FY2008 · RR
XENOBIOTIC BIOTRANSFORMATION IN CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE
$2,416Joel Edward Lavine · University Of California, San Diego · M01 · FY2010 · RR
Research Supplement to Promote Diversity in Health-Related Research: Undergraduate Students
$2,308Ruth E. Stark · City College Of New York · R16 · FY2024 · GM
MYOCARDIAL TRIGLYCERIDE AND LV PERFORMANCE ASSESS BY MRS AND MRI
$2,262Lidia S Szczepaniak · Ut Southwestern Medical Center · M01 · FY2007 · RR
STUDY OF N-3 FATTY ACID ON PLASMA TRIGLYCERIDE LEVELS
$2,149Todd T Brown · Johns Hopkins University · M01 · FY2007 · RR
MOLECULAR EPIDEMIOLOGY OF TYPE 2 DIABETES MELLITUS IN MEXICAN AMERICANS
$2,112Ralph A Defronzo · University Of Texas Hlth Science Center · M01 · FY2008 · RR
DEFINING HIGH RISK HEART DISEASE GENOMIC PROFILES FOR POTENTIAL INTERVENTIONS
$2,030Laura A Cox · Texas Biomedical Research Institute · P51 · FY2008 · RR
Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development
$2,000John H Streiff · Discoverybiomed, Inc. · R44 · FY2016 · DK
RANDOMIZED CONTROLLED TRIAL OF OMEGA 3 FATTY ACIDS IN THE TREATMENT
$1,809Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · M01 · FY2007 · RR
Functions of intracellular lipid-binding proteins
$1,807Noa Noy · Case Western Reserve University · R01 · FY2014 · DK
Hepatic TNF Receptor Associated Factor (TRAF) 3 Promotes Insulin Resistance through the Ubiquitination of Insulin Receptor Substrate (IRS) 1 and 2
$1,800Mark Jimenez-Canet · University Of Michigan At Ann Arbor · F32 · FY2017 · DK
p38 MAPK regulation of hepatic gluconeogenesis and lipogenesis
$1,680Wenhong Cao · The Hamner Institutes · R01 · FY2009 · DK
Role of estrogen-related receptors in cardiac and skeletal muscle
$1,660Janice M Huss · Beckman Research Institute/City Of Hope · R01 · FY2009 · DK
TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN (TONIC)
$1,611Arun J Sanyal · Virginia Commonwealth University · M01 · FY2010 · RR
CLINICAL TRIAL: TREATMENT OF NONALCOHOLIC STEATOHEPATITIS IN CHILDREN (TONI
$1,583Stephanie H Abrams · Baylor College Of Medicine · M01 · FY2011 · RR
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE2)
$1,582Elif Arioglu Oral · University Of Michigan At Ann Arbor · M01 · FY2007 · RR
The Lysosomal-Mitochondrial Axis in Nonalcoholic Fatty Liver Disease
$1,545Ariel Feldstein · Cleveland Clinic Lerner Com-Cwru · R01 · FY2009 · DK
MR Imaging of Non-Alcoholic Fatty Liver Disease
$1,545Claude B Sirlin · University Of California, San Diego · R01 · FY2009 · DK
Regional fat-re-accumulation following lipectomy in pre- and postmenopausal women
$1,540Rachael E Van Pelt · University Of Colorado Denver · R01 · FY2009 · DK
Purinergic Regulation of hepatocyte proliferation
$1,535Sundararajah Thevananther · Baylor College Of Medicine · R01 · FY2009 · DK
De novo lipogenesis in the pathogenesis of non-alcoholic fatty liver disease
$1,530Jean-Marc Schwarz · Touro University Of California · R01 · FY2009 · DK
PATHOGENESIS OF INSULIN RESISTANCE AND HEPATIC STEATOSIS IN PATIENTS WITH
$1,526Ned Snyder · University Of Texas Med Br Galveston · M01 · FY2007 · RR